Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir for outpatient treatment of COVID-19
IRCT20171219037964N3Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in coronavirus disease 2019 (COVID-19) comparing Favipiravir with Placebo (2 arms). Primary endpoints: Treatment failure and Side effects. Started Dec 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20171219037964N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171219037964N3.